Collegium Pharmaceutical ... (COLL)
| Bid | 24.47 |
| Market Cap | 858.56M |
| Revenue (ttm) | 631.45M |
| Net Income (ttm) | 69.19M |
| EPS (ttm) | 1.86 |
| PE Ratio (ttm) | 14.37 |
| Forward PE | 4.94 |
| Analyst | Buy |
| Ask | 29.4 |
| Volume | 412,105 |
| Avg. Volume (20D) | 406,201 |
| Open | 26.73 |
| Previous Close | 26.30 |
| Day's Range | 26.30 - 27.19 |
| 52-Week Range | 23.23 - 42.29 |
| Beta | 0.76 |
About COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatm...
Analyst Forecast
According to 5 analyst ratings, the average rating for COLL stock is "Buy." The 12-month stock price forecast is $44, which is an increase of 64.67% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Collegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025Collegium Pharmaceutical Inc. is a specialty pharma company with strong cash flow, high EBITDA margins, and a focus on non-abusive painkillers and ADHD drugs. The new CEO has a proven track record, pr...
1 month ago · seekingalpha.com
Collegium Pharmaceutical, Inc. (COLL) Q4 2024 Earnings Call TranscriptCollegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Vikram Karnani - Presiden...
